Zara Cosentino, commenting on the panel's composition, said that while the disclosure of conflicts is a positive transparency measure, it creates a structural problem: "especially when the people who stand to gain from growing access are the ones making the decision." Advisory meetings are subject to federal transparency requirements experts with financial stakes may serve, but relationships must be disclosed and the FDA is expected to explain why the panelist's expertise outweighs the conflict
Sources Article reviewed by Dr
Journal of Physiology-Paris 87:313327 Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH (2018) Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight